Table 3.

Curative high-dose-rate brachytherapy combined with external beam radiotherapy: in IIIA and IIIB lung cancers

Author	n	Clinical stage	EBRT (Gy)	Brachytherapy schemas (fr., dose)	LC (%)	OFS (%)
Mantz et al. [30]	39	T1-2 ≤ 5 cm	54-75.6	Trial: 1. 2-4 × 5-7 Gy 2. no BT	5 y: EBRT + BT – 58% EBRT – 32%	–
Huber et al. [51]	68	Advanced central lung tumors	60	Trial: 1. 2 × 4.8 Gy 2. no BT	5 vs. 3 mth (p = 0.052)	10 vs. 8 mth (p = 0.09)
Reddi et al. [52]	32	IIIA-IIIB	60	3 × 7.5 Gy	–	8 mth
Aygun et al. [53]	62	IIIA-IIIB	50-60	3-5 × 5 Gy	–	13 mth
Mehta et al. [54]	22	IIIA-IIIB	60	4 × 4 Gy	–	8.5 mth
Chang et al. [55]	54	IIIA-IIIB	20-70	3 × 7 Gy	–	–
Cotter et al. [56]	65	IIIA-IIIB	55-66	2-4 × 2.7-10 Gy	86%	8 mth
Speiser and Spratling [13]	50	IIIA-IIIB	60	3 × 7.5-10	80%	11 mth
Kohek et al. [57]	39	III	50-70	1-5 × 5.6	67%	13 mth
Zajac et al. [58]	24	III	50-61.2	3 × 5-10	82%	12 mth

LC – local control, OFS – overall free survival, BT – brachytherapy, LDR – low-dose-rate, MDR – medium-dose-rate, HDR – high-dose-rate, EBRT – external beam radiation therapy, y – years, Gy – Grey, mth – months, fr. – fraction